浏览全部资源
扫码关注微信
江西中医药大学 附属医院,南昌 330006
任凤梅,博士,副主任中医师,从事中药抗癌及中医治未病研究,E-mail:renfengmei666@163.com
张群芳,硕士,副主任护师,从事中药抗癌及中医养生研究,E-mail:31768816@qq.com
收稿日期:2022-07-04,
网络出版日期:2022-11-22,
纸质出版日期:2023-07-05
移动端阅览
任凤梅,杨超,曾晶晶等.薯蓣丸调控M1/M2型肿瘤相关巨噬细胞极化抗大肠癌进展的作用机制[J].中国实验方剂学杂志,2023,29(13):20-26.
REN Fengmei,YANG Chao,ZENG Jingjing,et al.Shuyuwan Regulates M1/M2 Polarization of Tumor-associated Macrophages to Inhibit Progression of Colorectal Cancer[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(13):20-26.
任凤梅,杨超,曾晶晶等.薯蓣丸调控M1/M2型肿瘤相关巨噬细胞极化抗大肠癌进展的作用机制[J].中国实验方剂学杂志,2023,29(13):20-26. DOI: 10.13422/j.cnki.syfjx.20230123.
REN Fengmei,YANG Chao,ZENG Jingjing,et al.Shuyuwan Regulates M1/M2 Polarization of Tumor-associated Macrophages to Inhibit Progression of Colorectal Cancer[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(13):20-26. DOI: 10.13422/j.cnki.syfjx.20230123.
目的
2
探讨薯蓣丸调控肿瘤相关巨噬细胞(TAMs)极化抑制大肠癌(CRC)进展的分子机制。
方法
2
构建结肠癌原位移植瘤裸鼠模型,雄性BALB/c-nu裸鼠(
n
=28,4周龄),随机分成4组,每组7只,模型组(生理盐水)、薯蓣丸低、中、高剂量组(1.725、2.310、2.895 g·kg
-1
·d
-1
)。每只裸鼠灌胃剂量为15 mL·kg
-1
,于接种瘤块后第9天开始灌胃处理,每日灌胃1次,每周6 d,第7天不灌胃,连续干预2周后处死裸鼠,剥离肿瘤标本;取部分结肠组织和肿瘤组织制作切片,苏木素-伊红(HE)染色进行病理观察;免疫组化(IHC)检测肿瘤组织中诱导型一氧化氮合酶(iNOS)、精氨酸酶-1(Arg-1)的表达;实时荧光定量聚合酶链式反应(Real-time PCR)检测肿瘤组织中白细胞介素-12(IL-12)、表皮细胞生长因子(EGF)、转化生长因子-
β
1
(TGF-
β
1
) mRNA表达;蛋白免疫印迹法(Western blot)检测肿瘤组织中iNOS、IL-12、EGF、TGF-
β
1
蛋白表达。
结果
2
与模型组比较,薯蓣丸能抑制裸鼠结肠癌肿瘤细胞的生长,病理可见不同程度的肿瘤细胞坏死。其中,薯蓣丸高剂量组对肿瘤细胞生长的抑制作用最强,肿瘤细胞形态基本消失;与模型组比较,薯蓣丸组明显上调了M1型TAMs相关细胞因子iNOS、IL-12表达(
P
<
0.05),下调了M2型TAMs相关细胞因子Arg-1、EGF、TGF-
β
1
的表达(
P
<
0.05),提示薯蓣丸处理后TAMs向M2型极化减弱,向M1型极化增强。
结论
2
薯蓣丸能够抑制结肠癌原位移植瘤的生长,其作用机制可能与阻断TAMs极化为M2型、促进TAMs向M1型极化有关。
Objective
2
To explore the molecular mechanism of Shuyuwan regulating polarization of tumor-associated macrophages (TAMs) to inhibit the progression of colorectal cancer (CRC).
Method
2
The nude mouse model of orthotopic transplantation of colon cancer was established. Male BALB/c-nu nude mice (
n
=28, 4 weeks old) were randomly assigned into 4 groups (
n
=7): Model group (normal saline) and low-, medium-, and high-dose (1.725, 2.310, 2.895 g·kg
-1
·d
-1
, respectively) Shuyuwan groups. On day 9 after the tumor block was inoculated, the mice were administrated by gavage with corresponding agents at a dose of 15 mL·kg
-1
once a day, 6 days a week, and no agent on the 7
th
day. After two consecutive weeks of intervention, the nude mice were sacrificed and the tumor samples were collected. A part of the colon tissue and the tumor tissue was used to prepare sections, and hematoxylin-eosin (HE) staining was performed for pathological observation. The expression of inducible nitric oxide synthase (iNOS) and arginase-1 (Arg-1) in the tumor tissue was detected by immunohistochemistry (IHC). The mRNA levels of interleukin-12 (IL-12), epidermal growth factor (EGF), and transforming growth factor-
β
1
(TGF-
β
1
) in the tumor tissue were determined by Real-time polymerase chain reaction (PCR). Western blot was employed to determine the protein levels of iNOS, IL-12, EGF, and TGF-
β
1
in the tumor tissue.
Result
2
Compared with the model group, Shuyuwan inhibited the growth of colon cancer cells in nude mice and caused the tumor cell necrosis in different degrees. The high-dose Shuyuwan group had the strongest inhibitory effect on the growth of tumor cells, which basically lost the normal morphology. Furthermore, Shuyuwan up-regulated the expression of iNOS and IL-12 in M1-type macrophages (
P
<
0.05) and down-regulated the expression of Arg-1, EGF, and TGF-
β
1
in M2-type macrophages (
P
<
0.05), which indicated the weakened polarization of macrophages toward M2 type and the enhanced polarization toward M1 type after treatment with Shuyuwan.
Conclusion
2
Shuyuwan can inhibit the growth of orthotopically transplanted colon tumor by blocking the polarization of TAMs to M2 type and promoting the polarization of TAMs to M1 type.
SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 .
彭丞 , 柴可群 . 中西医结合治疗大肠癌研究进展 [J]. 浙江中西医结合杂志 , 2022 , 32 ( 8 ): 779 - 782 .
王磊 , 时军利 , 王春青 , 等 . 大肠埃希菌对结直肠癌小鼠免疫相关细胞因子表达的影响 [J]. 免疫学杂志 , 2019 , 35 ( 12 ): 1043 - 1048 .
田慧香 , 马婕群 , 张彦兵 , 等 . 肿瘤相关巨噬细胞在结直肠癌转移及治疗中的作用 [J]. 医学综述 , 2021 , 27 ( 3 ): 498 - 502,507 .
朱静 , 尚广彬 , 孙慧娟 , 等 . 结肠癌的中医病机分析及复方治疗探索 [J]. 江西中医药 , 2018 , 49 ( 12 ): 75 - 78 .
黄彬 , 张红星 , 蒋曼君 . 对《金匮要略》薯蓣丸方证的认识 [J]. 广西中医药大学学报 , 2018 , 21 ( 4 ): 55 - 58 .
苗婷婷 . 黄煌运用薯蓣丸治疗化疗后肺癌的临床经验 [J]. 南京中医药大学学报 , 2016 , 32 ( 2 ): 198 - 200 .
夏克春 , 曾永蕾 , 郝皖蓉 . 薯蓣丸治疗癌性疲乏的临床疗效观察 [J]. 中日友好医院学报 , 2018 , 32 ( 5 ): 288 - 289,292 .
张春梅 , 曾柏荣 . 薯蓣丸治疗晚期胃癌恶病质24例临床观察 [J]. 湖南中医杂志 , 2019 , 35 ( 10 ): 49 - 51 .
张雲杰 , 谢甦 , 赵大尉 , 等 . 薯蓣丸对化疗4T1乳腺癌小鼠T淋巴细胞亚群的影响 [J]. 中国现代医学杂志 , 2018 , 28 ( 23 ): 6 - 11 .
熊炜 , 郭喜利 , 罗诗雨 , 等 . 近十年国内薯蓣丸的实验室研究进展 [J]. 湖北中医杂志 , 2016 , 38 ( 11 ): 81 - 82 .
杨杰 . 薯蓣丸剂量和用法对疗效的影响 [N]. 中国中医药报 , 2014-12-10 (004).
徐叔云 , 卞如濂 , 陈修 . 药理实验方法学 [M]. 北京 : 人民卫生出版社 , 2002 : 1465 - 1466 .
王磊 , 陈卫昌 , 陈桂林 , 等 . 人结肠癌裸鼠原位移植瘤模型的建立 [J]. 苏州大学学报:医学版 , 2005 , 25 ( 2 ): 201 - 204 .
刘宗超 , 李哲轩 , 张阳 , 等 . 2020全球癌症统计报告解读 [J]. 肿瘤综合治疗电子杂志 , 2021 , 7 ( 2 ): 1 - 13 .
冯莎 , 李慧明 . 薯蓣丸的临床应用与研究概述 [J]. 浙江中医杂志 , 2012 , 47 ( 9 ): 699 - 701 .
刘迅 , 周月 , 彭岚玉 , 等 . 薯蓣丸药理作用及临床应用研究概况 [J]. 中国中医药信息杂志 , 2022 , 29 ( 5 ): 153 - 156 .
MILLS C D , KINCAID K , ALT J M , et al . M-1/M-2 macrophages and the Th1/Th2 paradigm [J]. J Immunol , 2000 , 164 ( 12 ): 6166 - 6173 .
张子明 , 柴国静 , 宋淑霞 . 肿瘤相关巨噬细胞的极化及其对肿瘤治疗的影响 [J]. 中国免疫学杂志 , 2019 , 35 ( 8 ): 1018 - 1023 .
LOCATI M , CURTALE G , MANTOVANI A . Diversity, mechanisms, and significance of macrophage plasticity [J]. Annu Rev Pathol , 2020 , 15 : 123 - 147 .
LANKADASARI M B , MUKHOPADHYAY P , MOHAMMED S , et al . TAMing pancreatic cancer: Combat with a double edged sword [J]. Mol Cancer , 2019 , 18 ( 1 ): 48 .
CAILLOU B , TALBOT M , WEYEMI U , et al . Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma [J]. PLoS One , 2011 , 6 ( 7 ): e22567 .
刘利萍 , 张焱皓 , 李茂 , 等 . 调控巨噬细胞极化的相关信号通路及其调节机制研究进展 [J]. 中国免疫学杂志 , 2021 , 37 ( 6 ): 747 - 753 .
0
浏览量
40
下载量
2
CSCD
关联资源
相关文章
相关作者
相关机构